Get up to date on testing for METex14 and incorporating selective MET inhibitors into the care of your patients with METex14-altered NSCLC with an on-demand Webcast and downloadable slides from a live Webinar, video roundtables, podcasts, and expert-authored commentaries.
Download these slides for expert insights on MET as a new molecular target critical to the care of patients with lung cancer, including guidance on testing for MET exon 14 skipping mutations.
Download these slides for expert insights on MET-targeted therapies in development for MET-altered NSCLC, including tepotinib for METex14 mutation–positive disease.
Download these slides for expert insights on MET-targeted therapies in development for MET-altered NSCLC, including capmatinib for METex14 mutation–positive disease.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.